MicroRNAs were detected by microarray and subjected to bioinformatics analyses. Real-time PCR and Western blots were performed. The relationships between pathological changes and
microRNA expression were evaluated by linear regression analysis. Apoptosis and proliferation of cultured PD173074 mouse mesangial cells treated with microRNA inhibitor were determined by flow cytometry and MTT assay, respectively.
Results: Nine microRNAs, including miR-1187, miR320, miR-214, miR-34a, miR-762, miR-466f, miR-720, miR-744 and miR-1937b, were increased significantly. Another 9 microRNAs, including miR-1907, miR-195, miR-568, miR-26b, miR-703, miR-1196, miR-194, miR-805 and miR-192, were decreased remarkably in diabetic mice. The levels of microRNA repressing BCL2 decreased. Accordingly, BCL2 levels were found elevated and caspase-3 and caspase-8 levels decreased in the diabetic group. MicroRNA-195 expression was negatively related to glomeruli diameter, mesangial score and extracellular matrix (ECM) accumulation. Moreover, the microRNA-195 inhibitor protected mesangial cells from apoptosis and promoted the cellular proliferation in vitro.
Conclusions: These results demonstrated that the abated microRNA-195 expression protected mesangial cells from apoptosis, suggesting that the antiapoptosis in a microRNA-regulated manner may play an important role in the early stages of diabetic nephropathy.”
“Purpose:
VS-4718 mouse The purposes of this study of women with breast cancer receiving chemotherapy with/without radiation therapy were to determine whether: (1) subgroups of oncology outpatients can be identified based on a specific symptom cluster (i.e., pain, fatigue, sleep disturbances, depression); (2) these subgroups differ on outcomes (i.e.,
functional status, quality of life); (3) subgroup membership changes over time.
Methods: A secondary data analysis using data collected from 112 women at initial chemotherapy. Symptom and outcome measures were completed at three time points: baseline (i.e., the week before cycle two – T1); end of Y27632 cancer treatment (T2), end of the study (approximately one year after the start of chemotherapy – 13). Cluster analysis identified patient subgroups based on symptom severity scores.
Results: At T1 and T2, four patient subgroups were identified: ALL LOW (one or no symptom greater than the cut score), MILD (two symptoms), MODERATE (three or four symptoms), and ALL HIGH (four symptoms). At T3, three subgroups were identified: MILD, MODERATE and ALL HIGH. Subgroups with high severity levels of all four symptoms had poorer functional status and QOL at each time point than other subgroups (p < 0.001). Group membership changed over time.
Conclusions: Subgroups of patients with different symptom experiences were identified. For some patients severity of all four symptoms persisted months after cancer treatment.